Diabetic Kidney Disease: Finerenone, Nonsteroidal MRAs, and the FIDELIO/FIGARO Evidence
Sam Anderson
Finerenone: Mechanism and Rationale
Diabetic kidney disease is the leading cause of end-stage renal disease worldwide, and until recently, the pharmacologic toolkit for slowing its progression was limited to renin-angiotensin system blockade. The addition of SGLT2 inhibitors changed the landscape, and now finerenone — a nonsteroidal MRA with a distinct mechanism — provides a third pillar of renoprotective therapy. For the nephrologist, endocrinologist, or primary care physician managing patients with type 2 diabetes and CKD, understanding how finerenone fits alongside SGLT2 inhibitors and GLP-1 agonists is essential for building a comprehensive cardiorenal protection strategy.
Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) that differs structurally from spironolactone and eplerenone. Unlike steroidal MRAs, finerenone has no active metabolites, equal distribution between heart and kidney tissue, and a more favorable hyperkalemia profile. It blocks aldosterone-mediated inflammation and fibrosis in the kidney and cardiovascular system, targeting pathways complementary to ACE inhibitors/ARBs and SGLT2 inhibitors. The nonsteroidal structure eliminates the gynecomastia and sexual side effects associated with spironolactone.
FIDELIO-DKD: Renal Outcomes
FIDELIO-DKD enrolled 5,734 patients with type 2 diabetes and CKD (eGFR 25-75 mL/min with UACR 30-5000 mg/g)[1] already receiving maximally tolerated RAS blockade. Finerenone (10-20 mg daily) reduced the primary renal composite (kidney failure, sustained ≥40% eGFR decline, renal death) by 18% (HR 0.82, 95% CI 0.73-0.93, p=0.001)[2]. The key secondary cardiovascular composite (CV death, nonfatal MI, nonfatal stroke, HF hospitalization) was reduced by 14% (HR 0.86, 95% CI 0.75-0.99)[3]. The UACR reduction was approximately 31% at month 4[4], serving as an early indicator of treatment response.
FIGARO-DKD: Cardiovascular Outcomes
FIGARO-DKD enrolled a broader DKD population (7,437 patients, eGFR ≥25 with UACR 30-5000 mg/g, including earlier-stage CKD) and achieved its primary cardiovascular endpoint: 13% reduction in the composite of CV death, nonfatal MI, nonfatal stroke, and HF hospitalization (HR 0.87, 95% CI 0.76-0.98, p=0.03)[5]. The benefit was driven predominantly by a 29% reduction in heart failure hospitalization (HR 0.71, 95% CI 0.56-0.90)[6]. The pooled FIDELITY analysis (13,026 patients) confirmed consistent cardiorenal benefit across the DKD spectrum[8].
Practical Implementation: Dosing and Potassium Management
Finerenone is initiated at 10 mg daily if eGFR is 25-60 mL/min, or 20 mg daily if eGFR is ≥60 mL/min, provided serum potassium is ≤4.8 mEq/L. Potassium monitoring is required at 4 weeks, then periodically. In FIDELIO, hyperkalemia led to permanent discontinuation in 2.3% of finerenone patients versus 0.9% placebo, with hospitalization for hyperkalemia in 1.4% versus 0.3%[7]. Dietary potassium counseling, avoidance of concurrent potassium supplements, and dose reduction (20 mg to 10 mg) or temporary hold if potassium exceeds 5.5 mEq/L are essential management strategies.
The Multi-Pillar DKD Strategy: Combining Therapies
The 2024 KDIGO guidelines recommend a multi-pillar approach for DKD: maximally tolerated ACE inhibitor or ARB (pillar 1), SGLT2 inhibitor (pillar 2), finerenone (pillar 3), and GLP-1 receptor agonist (pillar 4 for patients with T2D needing additional glycemic control or weight management). In FIDELIO-DKD, only 4.6% of patients were on background SGLT2 inhibitor therapy, so real-world experience combining finerenone with dapagliflozin or empagliflozin is emerging. Early data suggest the combination is well-tolerated with a manageable hyperkalemia risk, as SGLT2 inhibitors have a modest potassium-lowering effect that may offset finerenone-induced hyperkalemia. Target HbA1c per ADA standards of care, blood pressure (<130/80 mmHg), and UACR should be reassessed iteratively as each pillar is added.
Sequencing the Pillars in Practice
For most patients with DKD, the practical sequencing begins with maximizing the ACE inhibitor or ARB to the highest tolerated dose — this remains the foundation and should not be skipped or underdosed. Next, add an SGLT2 inhibitor, which provides additive renoprotection through a complementary hemodynamic mechanism and carries the advantage of oral once-daily dosing with no titration required. Once both are established and tolerated, adding finerenone as the third pillar addresses the inflammatory and fibrotic pathways that RAS blockade and SGLT2 inhibition do not fully cover. The GLP-1 agonist layer is particularly relevant for patients who also need improved glycemic control or weight management, though its renal protection may apply more broadly based on the FLOW trial data. The key principle is that these agents are additive, not substitutive — each targets a different pathway, and the cumulative benefit of all four pillars exceeds any single agent alone.
Limitations and Practical Barriers
The multi-pillar approach to DKD management is evidence-based but faces real-world barriers. Cost and insurance coverage limit access to finerenone and GLP-1 agonists for many patients. Hyperkalemia monitoring adds complexity, particularly when combining finerenone with ACE inhibitors or ARBs in patients with more advanced CKD. The FIDELIO and FIGARO trials enrolled predominantly patients on RAS blockade alone — the data for combining finerenone with SGLT2 inhibitors are still maturing from real-world registries rather than randomized trials. And the clinical bandwidth required to implement, monitor, and titrate four renoprotective drug classes simultaneously in a busy practice is substantial. Despite these challenges, the trajectory of DKD management is clear: multi-pillar therapy will be the standard, and early adoption of this framework for the highest-risk patients is supported by the available evidence.
References
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD)
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD)
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD)
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD)
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes (FIGARO-DKD)
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes (FIGARO-DKD)
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD)
- FIDELITY pooled analysis of finerenone in FIDELIO-DKD and FIGARO-DKD (Agarwal et al.)
Frequently Asked Questions
What did FIDELIO-DKD show for finerenone in diabetic kidney disease?
How does finerenone differ from spironolactone?
What is the FIGARO-DKD cardiovascular benefit of finerenone?
How should finerenone be dosed and monitored for hyperkalemia?
What is the multi-pillar approach to DKD management?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine